*ST金山(600396.SH)一季度淨利升114.3%至1.88億元
格隆匯4月7日丨*ST金山(600396.SH)發佈2020年第一季度報告,實現營業收入20.23億元,同比增長0.52%;歸屬於上市公司股東的淨利潤1.88億元,同比增長114.30%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.82億元,同比增長131.05%;基本每股收益0.1275元。
根據現有市場條件和企業經營環境,預測下一報告期末,公司累計淨利潤與上年同期相比將大幅增加,主要原因一是公司狠抓經營管理及税率下降翹尾影響,發電邊際貢獻較同期增加;二是在供熱量增加的基礎上,公司狠抓跑冒滴漏治理,供熱經濟性較同期增加;三是持續推進提質增效,各項固定性成本費用較同期減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.